Article
Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports.
Oncotarget - 25 Jul 2017
Liu Yongmei, Zhang Yan, Zhang Li, Liu Bin, Wang Yongsheng, Zhou Xiaojuan, Li Yanying, Zhao Qian, Gong Youling, Zhou Lin, Zhu Jiang, Ding Zhenyu, Wang Jin, Peng Feng, Huang Meijuan, Li Lu, Ren Li, Lu You
Abstract excerpt
Epidermal growth factor receptor (EGFR) mutations are common in lung adenocarcinoma (ADC) but rare in squamous cell carcinoma (SQC). The efficacy of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) for SQC with EGFR mutations is unclear. The aim of this study was to evaluate the efficacy of EGFR-TKIs for these patients. We performed a retrospective matched-pair case-control study from 3 cancer centers, including 44...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.